![]() |
同义名 : | C390-0219 |
CAS号 : | 834903-43-4 | |
货号 : | A843612 | |
分子式 : | C25H19N3O4 | |
纯度 : | 99%+ | |
分子量 : | 425.44 | |
MDL号 : | MFCD06196075 | |
存储条件: |
Pure form Sealed in dry, 2-8°C In solvent -20°C:3-6个月-80°C:12个月 |
|
溶解度 : | - | |
动物实验配方: |
生物活性 | |||
---|---|---|---|
描述 | The G protein-coupled receptor 55 (GPR55), a lysophosphatidylinositol (LPI) receptor that is responsive to certain cannabinoids, has been implicated in several (patho)physiologic functions. CID-16020046 (40 nM – 10 μM) acts as an inverse agonist, inhibiting GPR55 constitutive activity with an IC50 of 0.15 μM. In HEK-GPR55 cells, pretreatment with increasing concentrations of CID-16020046 inhibited GPR55 agonist-induced intracellular Ca2+ release. Further, 2.5 μM CID-16020046 significantly inhibited the LPI (a GPR55 agonist)-induced ERK1/2 phosphorylation, GPR55 internalization and GPR55-mediated transcription factor activation in HEK-GPR55 cells[3]. In the DSS (dextran sulfate sodium) and TNBS (trinitrobenzene sulfonic acid) colitis models, treatment with CID-16020046 at a dosage of 20 mg/kg significantly reduced macroscopic scores and MPO (myeloperoxidase) activity as compared to vehicle-treated animals[4]. |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
2.35mL 0.47mL 0.24mL |
11.75mL 2.35mL 1.18mL |
23.51mL 4.70mL 2.35mL |
参考文献 |
---|